Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
P/E ratio for Aura Biosciences, Inc. (AURA)
P/E ratio as of 2023: -4.59
According to Aura Biosciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.59. At the end of 2022 the company had a P/E ratio of -5.49.
P/E ratio history for Aura Biosciences, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -4.59 |
| 2022 | -5.49 |
| 2021 | -14.41 |
| 2020 | -19.47 |
| 2019 | -17.87 |